<!doctype html>
<html>
  <head>
    <title>insight_160x600-300x600_expand-left</title>
    <meta charset="utf-8">
    <!-- disable IE11 phone number detection -->
    <meta name="format-detection" content="telephone=no">
    <meta name="viewport" content="initial-scale=1,maximum-scale=1,user-scalable=no">
    <meta name="ad.size" content="width=160, height=600">
    <link rel="stylesheet" href="css/main.css">
    
<script>
  var piLink = "https://www.shirecontent.com/?product=TAK&country=USA&language=ENG&contenttype=PI"; var seeMore = "https://www.takhzyro.com/hcp"; var seeTheResults = "https://www.takhzyro.com/hcp/efficacy"; var linkToLanding = "https://www.takhzyro.com"; 
</script>

    <script src="https://code.jquery.com/jquery-3.3.1.min.js" integrity="sha256-FgpCb/KJQlLNfOu91ta32o/NMZxltwRo8QtmkMRdAu8=" crossorigin="anonymous"></script>
    <script type="text/javascript" src="js/bundle.js"></script>
  </head>
  <body>
    <div id="main-panel" class="insight_160x600-300x600_expand-left">

      <div id="expanded-panel" class="expanded-panel">
        <div id="expanded-content-wrapper" class="expanded-content-wrapper">
          <button id="collapse-handler">
            <img src="img/x.png" alt="">
          </button>
          <div id="expanded-main-content" class="expanded-main-content main-content-wrapper">

            

  <img src="img/expanded-bg.jpg" class="background-image" alt="">
<div class="swoosh-wrap">
  <img src="img/expanded-swoosh.svg" class="swoosh" alt="">
</div>
<div class="main-content-inner">
  <video class="video" muted="">
    <source type="video/mp4" src="img/video-expanded.mp4">
  </video>
  <small class="legend" id="expanded-legend-1">Not an actual patient.</small>
  <div class="text-block" style="background-image: url(img/bird-in-bg.svg);">
    <h2 class="heading">
      <img src="img/Reimagine the way you_open.png" alt="">
    </h2>
    <h3 class="subheading">
      <img src="img/A first-of-its-kind open.png" alt="">
    </h3>
    <small class="small">
      *The recommended starting dose is 300 mg every 2 weeks. TAKHZYRO every 4 weeks is also effective and may be considered if the patient is well-controlled (eg, attack free) for more than 6&nbsp;months.
    </small>
    <button class="replay-btn">
      <img src="img/replay.svg" alt="">
    </button>
  </div>
</div>
  <!--enter page specific content here-->



          </div>
          <div id="expanded-middle-content" class="expanded-middle-content">

            

  
  <img src="img/takhzyro-us-color-cmyk.png" class="takhzyro-logo takhzyro-logo-primary" alt="">

<div class="btn-wrap">
  <div onclick="window.open(window.seeTheResults)" class="button click-tag"><img src="img/see-more-button@2x.png" alt=""></div>
</div>
<p>
  <span class="top-line">Scroll for Important Safety Information.</span>
  <br>
  TAKHZYRO is
  
  indicated to prevent HAE attacks in patients ≥12 years.
</p>
  <!--enter page specific content here-->



          </div>
          <div id="isi-container-wrapper" class="isi-container-wrapper">
            <div id="isi-container" class="isi-container">
              <div id="isi" class="isi">

                
  <div class="isi__content">
  <h6>
    Important Safety Information
  </h6>
  <p>
    <strong>Hypersensitivity reactions</strong> have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.
  </p>
  <p>
    <strong>Adverse Reactions:</strong> The most commonly observed adverse reactions (&ge;10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.
  </p>
  <p>
    <strong>Use in Specific Populations:</strong> The safety and efficacy of TAKHZYRO in pediatric patients &lt;12 years of age have not been established.
  </p>
  <p>
    No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.
  </p>
  <p>
    To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp. (a wholly-owned, indirect subsidiary of Shire plc) at <span class="nowrap">1‑800‑828‑2088</span>, or FDA at <span class="nowrap">1‑800‑FDA‑1088</span> or www.fda.gov/medwatch.
  </p>
  <p>
    <strong>Reference: 1.</strong> TAKHZYRO (lanadelumab-flyo subcutaneous injection) [prescribing information]. Lexington, MA: Shire LLC; 2018.
  </p>
  <img src="img/sl-full-rgb.png" alt="Shire logo">
  <p>
    &copy;2018 Shire US Inc., Lexington, MA 02421. <span class="nowrap">1‑800‑828‑2088</span>. All rights reserved.<br>
    TAKHZYRO is a trademark or registered trademark of Dyax Corp., a wholly-owned, indirect subsidiary of Shire plc. SHIRE and the associated logos are trademarks or registered trademarks of Shire.
    <br>
    <span class="nowrap">S41184 11/18</span>
  </p>
</div>


              </div>
            </div>
            <div onclick="window.open(window.piLink)" class="isi-btn click-tag">See Prescribing Information.</div>
          </div>
        </div>
      </div>

      <div id="collapsed-panel" class="collapsed-panel">
        <div id="collapsed-content-wrapper" class="collapsed-content-wrapper">
          <div id="collapsed-main-content" class="collapsed-main-content main-content-wrapper">

            

  <div class="top-content">
  <img src="img/swoosh.svg" class="swoosh" alt="">
  <video class="video" muted="">
    <source type="video/mp4" src="img/video-collapsed.mp4">
  </video>
  <div class="animated-block">
    <h2 id="heading-1" class="heading">
      <img src="img/REIMAGINE THE WAY YOU.png" alt="">
    </h2>
    <h2 id="heading-2" class="heading">
      <img src="img/A first-of-its-kind.png" alt="">
    </h2>
    <small id="legend-1" class="legend">HAE=hereditary angioedema.</small>
    <small id="legend-2" class="legend">Not an actual patient.</small>
    <small id="legend-3" class="legend">mAb=monoclonal antibody.</small>
    <div class="expand-handler-wrap">
      <button id="expand-handler">
        <img src="img/learn-more-btn@2x.png" alt="">
      </button>
    </div>
  </div>
</div>

<div class="middle-content">
  <img src="img/takhzyro-us-color-cmyk.png" alt="">
  <p>
    Scroll for Important Safety Information.
    <br>
    TAKHZYRO is indicated to prevent HAE attacks in patients ≥12 years.
  </p>
</div>
  <!--enter page specific content here-->



          </div>
          
          <div id="isi-collapsed-container-wrapper" class="isi-container-wrapper">
            <div id="isi-collapsed-container" class="isi-container">
              <div id="isi-collapsed" class="isi">

                
  <div class="isi__content">
  <h6>
    Important Safety Information
  </h6>
  <p>
    <strong>Hypersensitivity reactions</strong> have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.
  </p>
  <p>
    <strong>Adverse Reactions:</strong> The most commonly observed adverse reactions (&ge;10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.
  </p>
  <p>
    <strong>Use in Specific Populations:</strong> The safety and efficacy of TAKHZYRO in pediatric patients &lt;12 years of age have not been established.
  </p>
  <p>
    No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.
  </p>
  <p>
    To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp. (a wholly-owned, indirect subsidiary of Shire plc) at <span class="nowrap">1‑800‑828‑2088</span>, or FDA at <span class="nowrap">1‑800‑FDA‑1088</span> or www.fda.gov/medwatch.
  </p>
  <p>
    <strong>Reference: 1.</strong> TAKHZYRO (lanadelumab-flyo subcutaneous injection) [prescribing information]. Lexington, MA: Shire LLC; 2018.
  </p>
  <img src="img/sl-full-rgb.png" alt="Shire logo">
  <p>
    &copy;2018 Shire US Inc., Lexington, MA 02421. <span class="nowrap">1‑800‑828‑2088</span>. All rights reserved.<br>
    TAKHZYRO is a trademark or registered trademark of Dyax Corp., a wholly-owned, indirect subsidiary of Shire plc. SHIRE and the associated logos are trademarks or registered trademarks of Shire.
    <br>
    <span class="nowrap">S41184 11/18</span>
  </p>
</div>


              </div>
            </div>
            <div onclick="window.open(window.piLink)" class="isi-btn click-tag">See Prescribing Information.</div>
          </div>
          
        </div>
      </div>

    </div>
    <div id="error-wrapper">
      <pre id="errors"></pre>
    </div>
  </body>
</html>
